Familial and Hereditary Prostate Cancer by Definition in an Italian Surgical Series: Clinical Features and Outcome

Sacco, Emilio; Prayer-Galetti, Tommaso; Pinto, Francesco; Ciaccia, Matteo; Fracalanza, S.; Betto, Giovanni; Pagano, Francesco

doi:10.1016/j.eururo.2005.01.016

Cited by 29 publications

(22 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the FPC accounted for 20.9% of all PC cases and HPC for 6.6%; this was in line with previously reported data [15,16].…”

Section: Discussionsupporting

confidence: 81%

“…Age was the only significant parameter differing between groups; HPC was detected 4.7 years earlier than sporadic cases (p < 0001). Similarly, in a study population of men undergoing radical prostatectomy, Sacco et al found that the HPC group was five years younger than the SPC group (p < 0001), otherwise, no significant differences were observed in clinical and pathological variables [16,19]. Younger age at diagnosis among cases with family history is expected for a genetically determined disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer

Bentzon¹,

Lynnerup²,

Borre³

2012

OJU

View full text Add to dashboard Cite

Aim: To characterize familial prostate cancer including hereditary prostate cancer and assess the disease-free survival following radical prostatectomy. Methods: A self-administered written questionnaire was forwarded to 709 prostatectomized patients from the Aarhus Prostate Cancer Study containing questions about cases of prostate cancer (PC), age at diagnosis, vital status, and age at death for all first-degree relatives. Patients were then divided into groups according to their family history: hereditary prostate cancer (HPC), familial prostate cancer (FPC), and sporadic prostate cancer (SPC) groups. The information from a subset of both FPC (n = 17) and SPC (n = 17) groups were validated in the Danish Cancer Register and the Civil Registration System. Between groups, we described the association of age, prostatespecific antigen (PSA), postoperative Gleason score and T Stage. A Kaplan-Meier curve demonstrated postoperative disease-free survival in each group. Results: The response rate was 81% (574/709). About 21% of the patients were categorized in the FPC group, of which 7% were identified as having HPC. The median follow-up time was 63 months for HPC, 65 months for FPC and 88 months for SPC. Overall, there was no significant difference between groups in clinical features and disease-free survival except that patients with HPC were significantly associated with younger age than sporadic cases (p = 0.02). The proportion of self-reported PC diagnoses confirmed in the cancer register was 27.8%. The index persons with SPC reported no PC in first-degree relatives and none was found the cancer register. Conclusion: Overall, we found no difference in clinical characteristics and survival, following radical prostatectomy except that patients with HPC were younger at diagnosis. These results are in line with previously reported data.

show abstract

“…In this study, the FPC accounted for 20.9% of all PC cases and HPC for 6.6%; this was in line with previously reported data [15,16].…”

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer

Bentzon¹,

Lynnerup²,

Borre³

2012

OJU

View full text Add to dashboard Cite

show abstract

“…The causes of familial and sporadic cancers may differ and many studies have examined the possible differences in survival, however, overall with inconclusive results. For the commonest cancers, such as prostate and breast cancers, recent evidence has suggested no survival difference between the sporadic and familial diseases [3][4][5][6][7][8][9][10][11][12][13][14][15][16]. A similar survival experience was noted for familial and sporadic cancers for most of the cancer sites examined.…”

Section: Discussionsupporting

confidence: 60%

“…Many other studies have been done to examine the survival difference between familial and sporadic cancers, such as breast and prostate cancers [3][4][5][6][7][8][9][10][11][12][13][14][15][16]. However, the results were inconsistent at present, and study design limitations, such as such as small sample size, biased selection of study subjects and poor selection of controls, could be related to the inconsistent data.…”

Section: Introductionmentioning

confidence: 96%

Survival in common cancers defined by risk and survival of family members

Försti

Sundquist

et al. 2010

Oncol Rev

View full text Add to dashboard Cite

Studies on survival between familial and sporadic cancers have been inconclusive and only recent data on a limited number of cancers are available on the concordance of survival between family members. In this review, we address these questions by evaluating the published and unpublished data from the nation-wide Swedish Family-Cancer Database and a total of 13 cancer sites were assessed. Using sporadic cancer as reference, HRs were close to 1.0 for most of the familial cancers in both the offspring and parental generations, which suggested that survival in patients with familial and sporadic cancers was equal, with an exception for ovarian cancer with a worse prognosis. Compared to offspring whose parents had a poor survival, those with a good parental survival had a decreased risk of death for most cancers and HR was significantly decreased for cancers in the breast, prostate, bladder, and kidney. For colorectal and nervous system cancers, favorable survival between the generations showed a borderline significance. These data are consistent in showing that both good and poor survival in certain cancers aggregate in families. Genetic factors are likely to contribute to the results. These observations call for intensified efforts to consider heritability in survival as one mechanism regulating prognosis in cancer patients.

show abstract

“…Hereditary prostate cancer Sacco et al defined the three different epidemiological forms of prostate cancer: sporadic (occurring randomly in the population); familial (unpredictable clustering of prostate cancer in families); and hereditary (strong clustering and early onset of prostate cancer) [18]. Unlike other hereditary cancer syndromes, no single gene appears to be responsible for hereditary prostate cancer, but seven loci have been identified that contain genes potentially important in its development.…”

Section: Epidemiology Of Prostate Cancermentioning

confidence: 98%

Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices

Noe

Schroy

Demierre

et al. 2007

Cancer Causes Control

View full text Add to dashboard Cite

Prostate cancer, colorectal cancer, and melanoma are three malignancies that appear to have strong genetic components that can confer additional risk to family members. Screening tools, albeit controversial, are widely available to potentially aide in early diagnosis. Family members are now more attuned to the risks and benefits of cancer screening, thus, it is imperative that physicians understand the screening tools and how to interpret the information they provide. We reviewed the current literature regarding the cancer risks for individuals with a family history of prostate cancer, colon cancer, and melanoma, the current screening recommendations for family members, and actual screening practices of individuals with a family history of these malignancies. This review should serve as a guide for physicians and cancer control planners when advising their patients and the public regarding screening decisions.

show abstract

Familial and Hereditary Prostate Cancer by Definition in an Italian Surgical Series: Clinical Features and Outcome

Cited by 29 publications

References 41 publications

Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer

Clinico-Pathological Characterization of Hereditary, Familial and Sporadic Prostate Cancer

Survival in common cancers defined by risk and survival of family members

Increased cancer risk for individuals with a family history of prostate cancer, colorectal cancer, and melanoma and their associated screening recommendations and practices

Contact Info

Product

Resources

About